Westlake Village, CA – According to filings with the U.S. Securities and Exchange Commission, Arcutis Biotherapeutics is raising $94,500,000.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Frank Watanabe played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Arcutis Biotherapeutics

Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders.

To learn more about Arcutis Biotherapeutics, visit http://arcutis.com/

Contact:
Frank Watanabe, President and Chief Executive Officer
805-418-5006
frank.watanabe@arcutis.com
https://www.linkedin.com/in/frank-watanabe-419711/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved